A look at the Green Pharma Summit

The Green Pharma Sumit LinkedIn newsletter came out this week. Click here to read it. If you haven't joined our LinkedIn Green Pharma Summit Group, join today. You'll receive more updates and network with others who strive to make Pharma a more sustainable and eco-friendly industry.

If you were unable to attend the Green Pharma Summit, we have notes on the discussions during event’s roundtables, networking breaks and panels focusing on Pharma’s opportunities, challenges and actions going forwards. See what they discussed here:
http://bit.ly/GPPres

Share this article with your social network, just click below to share now!

Share |

Countdown to Green Pharma

The latest LinkedIn Update for the Green Pharma Summit LinkedIn group went out this morning! As we're gearing up for the event next week, we thought you'd like to know what will be happening at the event! If you'll be at the event, use #greenpharma when you Twitter so we can follow along with you at the event!

Read the newsletter here:
http://www.iirusa.com/upload/wysiwyg/New%20Media/LINewsletter071009.htm


The Green Pharma Summit is about how Pharma is going green. Pharmaceutical companies are discovering that going green is not just for altruistic reasons, but that going green actually has benefits to the bottom line. Going green saves and makes money. If you'd like to network with other professionals who are working in the Green Pharma field, join our Green Pharma LinkedIn Group!

Share this article with your social network, just click below to share now!

Share |

The Pharma Industry and Energy Usage

Pharmaceutical companies implementing environmental sustainability initiatives stand to gain immediate cost savings. These savings will not take years to appreciate; tremendous cost savings can be seen within the first 12 months. Here’s a snapshot of just some of the cost savings pharmaceutical companies have experienced in their first year of initiating sustainability programs:

• A pharmaceutical company making a strong move towards green chemistry has the potential to see up to a 40% hazardous waste reduction in one year.
• AstraZeneca’s green chemistry efforts have lowered their material and energy costs, reducing the cost of API generation by 80%
• Baxter’s EHS programs have generated cost savings of $4.4 million
• A recent in-depth analysis of Novartis’s energy efficiency and waste reduction programs have shown that the $20 million dollar investment was recouped in 10 months
• Novartis’s energy efficient pilot project for Penicillin V production has delivered annual cost savings of $5.1 million

In such troubling economic times, the millions of dollars in cost savings through going green will have a tremendous impact on your company’s bottom line and with shareholders. The Green Pharma Summit gathers the pharma industry’s green leaders, who will share with you successful strategies to implement sustainability programs so that your company can start benefiting from cost savings and efficiency improvements right away.


The Green Pharma Summit is about how Pharma is going green. Pharmaceutical companies are discovering that going green is not just for altruistic reasons, but that going green actually has benefits to the bottom line. Going green saves and makes money. If you'd like to network with other professionals who are working in the Green Pharma field, join our Green Pharma LinkedIn Group!

Share this article with your social network, just click below to share now!

Share |

Big Pharma gets green kudos for carbon-tracking

Posted on Carbon Offsets Daily, Climate Counts recently released a scorecard for pharma. Great news, pharma outscored media on a one-to-100 scale, with higher scores indicating greater commitment to the environment, top drugmaker AstraZeneca tallied a 76, with Johnson & Johnson on its heels at 75. Twelve more pharma companies scored 50 or higher. By contrast, top-scoring media firm General Electric (which owns NBC) boasted a 71, and second-placer News Corp. got a 63. In third place, Disney came in with a measly 25.

Because AstraZeneca scored so highly, do you think other organizations in Big Pharma will follow?

The Green Pharma Summit is about how Pharma is going green. Pharmaceutical companies are discovering that going green is not just for altruistic reasons, but that going green actually has benefits to the bottom line. Going green saves and makes money. If you'd like to network with other professionals who are working in the Green Pharma field, join our Green Pharma LinkedIn Group!

Share this article with your social network, just click below to share now!

Share |

Green Pharma Summit: Who you're going to hear from

Who is going to be at this year's Green Pharma Summit?

Over 20 Leading Pharmaceutical and Industry sustainability experts providing you with green strategies and tools that you can implement immediately upon your return:

Pharma/Biotech
• Michael Whaley, Director of Environmental Health and Safety, Allergan
• Ann Lee-Jeffs, Manager, Worldwide Environmental Affairs, Johnson & Johnson
• Ingrid Mergelsberg, PhD, Director, Chemical and Physical Sciences (Chemical Development), Schering -Plough Research Institute
• Concepcion Jimenez-Gonzalez, PhD, Director, Operational Sustainability, GlaxoSmithKline
• Peter Dunn, PhD, Green Chemistry Team Leader, Pfizer
• Marcus Chung, MBA, Director, Corporate Citizenship, McKesson Corporation
• James Hagan, Vice President, Corporate Environment, Health, Safety and Sustainability, GlaxoSmithKline
• Norman Goldschmidt, Principal, Pharma Engineering Advisors, and Former Sr. Director of Global Engineering & Design, Bristol-Myers Squibb

Government
• Chen Wen, Office of Prevention, Pesticides and Toxics, US Environmental Protection Agency
• Åke Wennmalm, MD, PhD, Professor, Environmental Director, Stockholm County Council
• Michael Gonzalez, National Risk Management Research Lab, US Environmental Protection Agency
• Walt Tunnessen, National Program Director for the EPA Energy Star® Program, US Environmental Protection Agency

Academia
• Terrence J. Collins, PhD, Thomas Lord Professor of Chemistry, Director, Institute for Green Science, Carnegie Mellon University
• William Trombetta, Professor of Marketing, St. Joseph’s University

Enviromental Guru Keynote
• Kim Carlson, Founder, Earthsmart Consumer and author of Green Your Work: Boost Your Bottom Line While Reducing Your Carbon Footprint

The Green Pharma Summit is about how Pharma is going green. Pharmaceutical companies are discovering that going green is not just for altruistic reasons, but that going green actually has benefits to the bottom line. Going green saves and makes money. If you'd like to network with other professionals who are working in the Green Pharma field, join our Green Pharma LinkedIn Group!

Share this article with your social network, just click below to share now!

Share |

Zero discharge policy can earn Pharma a few dollars

Recently in the Business Standard, B Krishna Mohan wrote about how some companies are taking their waste and selling it for profit. Waste discharged while making Pharmaceuticals can be turned around and used as raw materials in other industries, which can often be purchased at up to a 50% discount. Some companies have even gone as far as to call for a zero-discharge policy, which eliminates all liquid discharge.

Virchow Laboratories sells sodium sulphate, gypsum, solvents and flyash generated at the company’s Hyderabad and Visakhapatnam bulk drug manufacturing units. While sodium sulphate is the raw material for the soap and detergent industry, gypsum finds use in the cement industry and solvents are the key raw materials for the paint industry. The fly-ash is used for making bricks, says Virchow chairman M Narayana Reddy.

Read the full article here. If you're interested in networking with other professionals who are interested in Green Pharma, join our Green Pharma LinkedIn group and Follow us on Twitter!

Share this article with your social network, just click below to share now!

Share |

What are companies doing to make Pharma greener?

The pharmaceutical sector is working hard to adopt more sustainable and environmentally friendly practices that offer measurable improvements without sacrificing the bottom-line. As more and more environmental health and sustainability professionals turn their attention to green initiatives, the c-suite is looking to these programs to deliver measurable value with quantifiable impact.

At the Green Pharma Summit, learn how…
* Johnson & Johnson and GlaxoSmithKline adopted successful greening strategies to engage all departments
* Pfizer implemented a company-wide Green Chemistry Team to substantially reduce waste throughout their manufacturing and chemical development processes
* Allergan earned the US EPA Energy Star® Partner of the Year Award by implementing Green R&D and manufacturing practices for energy efficiencies and cost savings
* Schering-Plough influences smart solvent and reagent choices by implementing solvent selection guides to encourage Green decisions from the start

To network with other professionals in the Green Pharma field, we invite you to join our LinkedIn group here.

Share this article with your social network, just click below to share now!

Share |

Pharamceuticals in the drinking water

In a recent article by the AP, US companies have dropped 271 million pounds of pharmaceuticals in the water of the United States. They do this legally. Of the compounds released, 22 are classified as industrial chemicals by the EPA, while the FDA classifies them as active Pharma ingredients. This number may be off as well, because the federal government has limited tracking on these chemicals.

Last year, the AP reported that trace amounts of a wide range of pharmaceuticals — including antibiotics, anti-convulsants, mood stabilizers and sex hormones — have been found in American drinking water supplies. Including recent findings in Dallas, Cleveland and Maryland's Prince George's and Montgomery counties, pharmaceuticals have been detected in the drinking water of at least 51 million Americans.

Trace amounts of drugs in the drinking water been shown to harm fish, frogs and other aquatic animals. Human cells in laboratories have also failed to grow properly after being exposed to small amounts of pharmaceuticals.

For the complete article, read it here. If you're interested in networking with other professionals who are interested in Green Pharma, join our Green Pharma LinkedIn group and Follow us on Twitter!

Share this article with your social network, just click below to share now!

Share |

Web Seminar: The Role of PharmEcovigilance in Reducing the Environmental Footprint of Pharmaceuticals

We'd like to remind you about the web seminar for the Green Pharma Summit

Web Seminar: The Role of PharmEcovigilance in Reducing the Environmental Footprint of Pharmaceuticals

Ilene S Ruhoy, MD, PhD, Assistant Professor, Touro University and US EPA Environmental Sciences Division

Tuesday, April 14, 2009 12:00 PM - 1:00 PM EDT

The prescribing and usage of medications have ramifications extending far beyond conventional medical care. The pharmaceutical and healthcare industries have an environmental footprint because the active pharmaceutical ingredients (APIs) can enter the environment as contaminants by a variety of routes, primarily from excretion, bathing, and disposal. Disposal of unwanted, leftover medications by flushing into sewers has been considered a secondary route - - one that supposedly does not contribute substantially to overall environmental loadings of APIs. This presentation is an examination of secondary routes of API release to the environment and for direct but unintentional human exposure. These routes include: (a) bathing, washing, and laundering, and (b) disposal of unused and partially used high-content medical devices. Understanding these secondary routes is important from the perspective of pollution prevention, as well as for reducing the incidence of unintentional and purposeful poisonings of humans and pets, and for improving the quality and cost-effectiveness of healthcare.

Sign up here:
https://www1.gotomeeting.com/register/909165450

Use priority code:G1M1481W1Blog/LI

Share this article with your social network, just click below to share now!

Share |

Bringing in the Green

Porcher L. Taylor, III and David E. Kitchen write on the green initiatives that Pharma must do in order to be environmentally friendly and help boost their brand image and ROI. In their piece, Bringing in the Green, Taylor and Kitchen lay out simple plans that Pharma should consider when aiming to be green. These initatives, according to the writers, are clear and compelling financial, corporate-citizenship, and consumer-management arguments for the industry to aggressively become eco-friendly. The first pharma company that adopts these Green practices and markets itself in this way may have a major competitive advantage within reach. To read their practices, review the article here.

We'd like to hear your thoughts on green inititatives throughout Pharma on our Future of BioPharma LinkedIn group and greenPharma LinkedIn group. Join us today!

Share this article with your social network, just click below to share now!

Share |

Web Seminar: The Role of PharmEcovigilance in Reducing the Environmental Footprint of Pharmaceuticals

Ilene S Ruhoy, MD, PhD, Assistant Professor, Touro University and US EPA Environmental Sciences Division

Tuesday, April 14, 2009 12:00 PM - 1:00 PM EDT

The prescribing and usage of medications have ramifications extending far beyond conventional medical care. The pharmaceutical and healthcare industries have an environmental footprint because the active pharmaceutical ingredients (APIs) can enter the environment as contaminants by a variety of routes, primarily from excretion, bathing, and disposal. Disposal of unwanted, leftover medications by flushing into sewers has been considered a secondary route - - one that supposedly does not contribute substantially to overall environmental loadings of APIs. This presentation is an examination of secondary routes of API release to the environment and for direct but unintentional human exposure. These routes include: (a) bathing, washing, and laundering, and (b) disposal of unused and partially used high-content medical devices. Understanding these secondary routes is important from the perspective of pollution prevention, as well as for reducing the incidence of unintentional and purposeful poisonings of humans and pets, and for improving the quality and cost-effectiveness of healthcare.

Sign up here:
https://www1.gotomeeting.com/register/909165450

Use priority code:G1M1481W1Blog/LI

Share this article with your social network, just click below to share now!

Share |

Pharma's pressure to be socially responsible

Future Pharmaceutical recently wrote a article on the variety of ways that Pharma companies are choosing to both protect the environment and show their involvement in both humanitarian and environmental projects. Some of the companies in the article have started using green vehicles for distribution and transportation. Others have made efforts to make meetings greener and another option is to choose sustainable suppliers and sustainable distribution centers.

If you're interested in joining a community of Pharma professionals who are committed to make their Pharma projects that protect the enviornment and are sustainable, join us at the Green Pharma LinkedIn group.

Share this article with your social network, just click below to share now!

Share |

Green Pharma Summit

Have you heard about the Green Pharma Summit? It'll be taking place July 20-21 in Philadelphia, PA! Find out more information at our webpage and sign up to get the latest updates!

And if you're interested in networking and communicating with other professionals who are working on going green in the Pharma industry, join our Green Pharma LinkedIn Group!

Share this article with your social network, just click below to share now!

Share |